Here is the rundown on market activity for Juno Therapeutics, Inc. (NASDAQ:JUNO). Richard Klausner, Director sold $569,520 worth of shares at an average price of $23.73 on June 7th. That brings the Director’s holdings to $19,567,877 as reported to the SEC. Jay T. Flatley, Director disclosed the purchase of 20,000 shares of JUNO stock. The shares sold for $24.76. Flatley now owns $532,340 of the stock per the Form 4 SEC filing.
Director Anthony B. Evnin disclosed the purchase of 8,000 shares of (JUNO). The shares were bought on March 10th for an average price of $22.11. The Director now owns $1,260,049 of the stock according to the SEC filing.
Juno Therapeutics, Inc. (Juno), launched on August 5, 2013, is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas..
Here are a few other firms who have also updated their positions. As of the end of the quarter Proficio Capital Partners LLC had acquired a total of 57 shares growing its stake by 570.0%. The value of the total investment in Juno Therapeutics, Inc. increased from $0 to $2,000 a change of $2,000 since the last quarter. As of quarter end Morgan Stanley had sold 50 shares trimming its holdings by 1.4%. The value of the company’s investment in Juno Therapeutics, Inc. went from $68,000 to $79,000 increasing 16.2% quarter over quarter.
Tower Research Capital LLC (trc) cut its position by selling 6,958 shares a decrease of 100.0% as of 03/31/2017. Tower Research Capital LLC (trc) now holds 2 shares valued at $0. The total value of its holdings decreased 100.0%. As of the end of the quarter Goldman Sachs Group Inc had acquired a total of 13,506 shares growing its position 72.1%. The value of the investment in Juno Therapeutics, Inc. increased from $353,000 to $716,000 a change of 102.8% quarter to quarter.
On June 8 the company was downgraded from “Neutral” to “Sell” by BTIG Research. On December 6, 2016 the stock rating was changed to a “Market Perform” by Raymond James which was a cut from the previous “Outperform” rating.
On November 28 Leerink Swann made no change to the company rating of “Outperform” and moved down the price target from $74.00 to $34.00. SunTrust Robinson Humphrey both downgraded the stock and lowered the price target on November 25 changing the price objective from $50.00 to $25.00 and cutting the rating from “Buy” to “Hold”.
On November 25 the stock rating was downgraded to “Hold” from “Buy” and a price target of $25.00 was set in a report issued by SunTrust Robinson Humphrey. On November 4 the company was rated “Neutral” in a report from BTIG Research which was a boost from the previous “Sell” rating.
The company is now down from yesterday’s close of $22.36. Shares last traded at $21.68 just a bit lower than the 50 day moving average which is $24.36 and a tad below the 200 day moving average of $22.15. The 50 day moving average was down by -11.01% and the 200 day average went down $-0.47 or -2.12%.
As of the last earnings report the EPS was $-2.50 and is estimated to be $-2.99 for the current year with 104,145,000 shares now outstanding. Analysts expect next quarter’s EPS to be $-0.72 and the next full year EPS is projected to be $-3.17.
Investors are feeling more bullish lately looking at the fall in short interest. The firm had a fall in short interest from May 15, 2017 to April 28, 2017 of -0.01%. Short interest fell 954 over that timeframe. Days to cover decreased from 14.9 to 10.8 and the percentage of shorted shares is 0.16% as of April 28.